Pyrimidine-morpholine hybrids as potent druggable therapeutics for Alzheimer’s disease: Synthesis, biochemical and in silico analyses

Iraji, 2020, Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands, Bioorg. Chem., 97, 10.1016/j.bioorg.2020.103649 Minati, 2009, Current concepts in Alzheimer’s disease: a multidisciplinary review, Am. J. Alzheimers Dis. Other Demen., 24, 95, 10.1177/1533317508328602 Du, 2018, Alzheimer’s disease hypothesis and related therapies, Transl. Neurodegener., 7, 1, 10.1186/s40035-018-0107-y Mottaghipisheh, 2021, Linarin, a glycosylated flavonoid, with potential therapeutic attributes: A comprehensive review, Pharmaceuticals., 14, 1104, 10.3390/ph14111104 Ballard, 2005, Cholinesterases: Roles in the brain during health and disease, Curr. Alzheimer Res., 2, 307, 10.2174/1567205054367838 Saeed, 2014, Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases, Eur. J. Med. Chem., 78, 43, 10.1016/j.ejmech.2014.03.015 Colović, 2013, Acetylcholinesterase inhibitors: Pharmacology and toxicology, Curr. Neuropharmacol., 11, 315, 10.2174/1570159X11311030006 Grossberg, 2003, Cholinesterase inhibitors for the treatment of Alzheimer’s disease: Getting on and staying on, Curr. Ther. Res. Clin. Exp., 64, 216, 10.1016/S0011-393X(03)00059-6 Pourtaher, 2022, Design, synthesis, in silico and biological evaluations of novel polysubstituted pyrroles as selective acetylcholinesterase inhibitors against Alzheimer’s disease, Sci. Rep., 12, 15236, 10.1038/s41598-022-18224-6 Lalut, 2020, Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT4 receptors activities for the treatment of Alzheimer's disease, Sci. Rep., 10, 3014, 10.1038/s41598-020-59805-7 Pourshojaei, 2019, Phenoxyethyl Piperidine/Morpholine Derivatives as PAS and CAS Inhibitors of Cholinesterases: Insights for Future Drug Design, Sci. Rep., 9, 19855, 10.1038/s41598-019-56463-2 Pant, 2022, Pyrimidine analogues for the management of neurodegenerative diseases, Eur. J. Med. Chem. Rep., 6 Bortolami, 2021, New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and In Vitro and In Cellulo Evaluation, ACS Chem. Nerosci., 12, 4090, 10.1021/acschemneuro.1c00485 Dubois, 2010, Revising the definition of Alzheimer’s disease: A new lexicon, Lancet Neurol., 9, 1118, 10.1016/S1474-4422(10)70223-4 Aisen, 2011, Report of the task force on designing clinical trials in early (predementia) AD, Neurology, 76, 280, 10.1212/WNL.0b013e318207b1b9 Dubois, 2016, Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria Alzheimer’s & dementia, J. Alzheimer’s Assoc., 12, 292 Vitaku, 2014, Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals, J. Med. Chem., 57, 10257, 10.1021/jm501100b Nadar, 2022, Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity, Chem. Biol. Drug Des., 100, 818, 10.1111/cbdd.14001 Bhalgat, 2014, Novel pyrimidine and its triazole fused derivatives: synthesis and investigation of antioxidant and anti-inflammatory activity, Arab. J. Chem., 7, 986, 10.1016/j.arabjc.2010.12.021 Huang, 2012, One-pot synthesis and antiproliferative evaluation of pyrazolo[3,4-d]pyrimidine derivatives, Tetrahedron, 68, 9658, 10.1016/j.tet.2012.09.054 Liu, 2016, Discovery of Pyrazolo[1,5 a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent, ACS Med. Chem. Lett., 7, 671, 10.1021/acsmedchemlett.5b00485 Kourounakis, 2020, Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules, Med. Res. Rev., 40, 709, 10.1002/med.21634 Kumari, 2020, Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR), Bioorg. Chem., 96, 10.1016/j.bioorg.2020.103578 Al-Ghorbani, 2015, Piperazine and morpholine: synthetic preview and pharmaceutical applications, J. Chem. Pharm. Res., 7, 281 Naim, 2015, A review on pharmacological profile of Morpholine derivatives, Int. J. Pharmacol. Pharm. Sci., 3, 40 Kumar, 2016, Emphasizing morpholine and its derivatives (Maid): typical candidate of pharmaceutical importance, Int. J. Chem. Sc., 14, 1777 Arshad, 2019, Revealing quinquennial journey of morpholine: a SAR based review, Eur. J. Med. Chem., 167, 324, 10.1016/j.ejmech.2019.02.015 Hassan, 2002, Aryl−aryl bond formation one century after the discovery of the Ullmann reaction, Chem. Rev., 102, 1359, 10.1021/cr000664r Dong, 2019, A general asymmetric copper-catalysed Sonogashira C (sp 3)–C (sp) coupling, Nat. Chem., 11, 1158, 10.1038/s41557-019-0346-2 Yeung, 2011, Catalytic dehydrogenative cross-coupling: forming carbon-carbon bonds by oxidizing two carbon-hydrogen bonds, Chem. Rev., 111, 1215, 10.1021/cr100280d Leenders, 2015, Transition metal catalysis in confined spaces, Chem. Soc. Rev., 44, 433, 10.1039/C4CS00192C Choi, 2017, Transition metal-catalyzed alkyl-alkyl bond formation: Another dimension in cross-coupling chemistry, Science, 356, 6334, 10.1126/science.aaf7230 Muto, 2015, Decarbonylative organoboron cross-coupling of esters by nickel catalysis, Nat. Commun., 6, 7508, 10.1038/ncomms8508 Li, 2020, Reaction scope and mechanistic insights of nickel-catalyzed migratory Suzuki-Miyaura cross-coupling, Nat. Commun., 11, 417, 10.1038/s41467-019-14016-1 Hazari, 2017, Well-defined nickel and palladium precatalysts for cross-coupling, Nat. Rev. Chem., 1, 0025, 10.1038/s41570-017-0025 Guo, 2019, Nickel-catalyzed Suzuki-Miyaura cross-couplings of aldehydes, Nat. Commun., 10, 1957, 10.1038/s41467-019-09766-x Ye, 2019, Palladium-bearing intermetallic electride as an efficient and stable catalyst for Suzuki cross-coupling reactions, Nat. Commun., 10, 5653, 10.1038/s41467-019-13679-0 Felpin, 2019, Biaryl synthesis with arenediazonium salts: cross-coupling, CH-arylation and annulation reactions, Chem. Soc. Rev., 48, 1150, 10.1039/C8CS00453F Miyaura, 1995, Palladium-catalyzed cross-coupling reactions of organoboron compounds, Chem. Rev., 95, 2457, 10.1021/cr00039a007 Sherwood, 2019, Solvent effects in palladium catalysed cross-coupling reactions, Green Chem., 21, 2164, 10.1039/C9GC00617F Hooshmand, 2019, Recent advances in the Suzuki-Miyaura cross-coupling reaction using efficient catalysts in eco-friendly media, Green Chem., 21, 381, 10.1039/C8GC02860E Magano, 2011, Large-scale applications of transition metal-catalyzed couplings for the synthesis of pharmaceuticals, Chem. Rev., 111, 2177, 10.1021/cr100346g Negishi, 2011, Magical power of transition metals: past, present, and future, Angew. Chem. Int. Ed., 50, 6738, 10.1002/anie.201101380 Torborg, 2009, Recent applications of palladium-catalyzed coupling reactions in the pharmaceutical, agrochemical, and fine chemical industries, Adv. Synth. Catal., 351, 3027, 10.1002/adsc.200900587 Lipton, 2003, The synthesis of OSU 6162: efficient, large-scale implementation of a Suzuki coupling, Org. Process Res. Dev., 7, 385, 10.1021/op025620u Conlon, 2006, Process development and large-scale synthesis of a PDE4 inhibitor, Org. Process Res. Dev., 10, 36, 10.1021/op050116l Doucet, 2007, Palladium coupling catalysts for pharmaceutical applications, Curr. Opin. Drug Discov. Devel., 10, 672 Roughley, 2011, The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates, J. Med. Chem., 54, 3451, 10.1021/jm200187y Khan, 2014, Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis, Bioorg. Med. Chem., 22, 6163, 10.1016/j.bmc.2014.08.026 Khan, 2014, Synthesis, crystal structure and biological evaluation of some novel 1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazoles and 1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazines, Eur. J. Med. Chem., 78, 167, 10.1016/j.ejmech.2014.03.046 Khan, 2015, Exploration of a library of triazolothiadiazole and triazolothiadiazine compounds as a highly potent and selective family of cholinesterase and monoamine oxidase inhibitors: design, synthesis, X-ray diffraction analysis and molecular docking studies, RSC Adv., 5, 21249, 10.1039/C5RA00906E Ibrar, 2018, Combined in vitro and in silico studies for the anticholinesterase activity and pharmacokinetics of coumarinyl thiazoles and oxadiazoles, Front. Chem., 6, 61, 10.3389/fchem.2018.00061 Shehzadi, 2019, One-pot four-component synthesis of thiazolidin-2-imines using CuI/ZnII dual catalysis: A new class of acetylcholinesterase inhibitors, Bioorg. Chem., 84, 518, 10.1016/j.bioorg.2018.12.002 Zaib, 2021, Hybrid Quinoline-Thiosemicarbazone Therapeutics as a New Treatment Opportunity for Alzheimer’s Disease-Synthesis, In Vitro Cholinesterase Inhibitory Potential and Computational Modeling Analysis, Molecules, 26, 6573, 10.3390/molecules26216573 Munir, 2021, Microwave-Assisted Synthesis of (Piperidin-1-yl)quinolin-3-yl)methylene)hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach, Molecules, 26, 656, 10.3390/molecules26030656 Ali, 2022, Discovery of potent and selective dual cholinesterases and β-secretase inhibitors in pomegranate as a treatment for Alzheimer’s disease, Bioorg. Chem., 129 Woodring, 2017, Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation, Eur. J. Med. Chem., 141, 446, 10.1016/j.ejmech.2017.10.007 Ellman, 1961, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7, 88, 10.1016/0006-2952(61)90145-9 Nachon, 2013, Crystal structures of human cholinesterases in complex with huprine W and tacrine: Elements of specificity for anti-Alzheimer’s drugs targeting acetyl- and butyrylcholinesterase, J. Biochem., 453, 393, 10.1042/BJ20130013 Iqbal, 2015, Biological evaluation of halogenated thioureas as cholinesterases inhibitors against Alzheimer’s disease & molecular modeling studies, Lett. Drug Des. Discov., 12, 488, 10.2174/1570180812666141201222247 P.P. Labute, P. Protonate, 3D, Chemical Computing Group, 2007. Available online: http://www.chemcomp.com/journal/proton.htm (accessed on 10th September 2022). Chemical Computing Group's Molecular Operating Environment (MOE) MOE 2019. 0201 Available online: http://www.chemcomp.com/MOEMolecular_Operating_Environment.htm (accessed on 10th September 2022). LeadIT Version 2.3.2; BioSolveIT GmbH: Sankt Augustin, Germany, 2017. Available online: www.biosolveit.de/LeadIT (accessed on 10th September 2022). Schneider, 2013, A consistent description of hydrogen bond and dehydration energies in protein-ligand complexes: Methods behind the HYDE scoring function, J. Comput. Aided Mol. Des., 27, 15, 10.1007/s10822-012-9626-2 BIOVIA Discovery Studio Client v19.1.0.18287. Accelrys Discovery Studio; Accelrys Software Inc.: San Diego, CA, USA, 2019 (accessed on 10th September 2022). Gordon, 2005, H++: a server for estimating pKas and adding missing hydrogens to macromolecules, Nucleic Acids Res., 33, 368, 10.1093/nar/gki464 D.A. Case, K. Belfon, I.Y. Ben‐Shalom, S.R. Brozell, D.S. Cerutti, T.E. Cheatham, V.C. III, T.A. Darden, R.E. Duke, G. Giambasu, M.K. Gilson, AMBER2020, university of California, San Fransisco. J. Amer. Chem. Soc. 142 (2020) 3823-3835. https://www.researchgate.net/publication/233420507. Maier, 2015, ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB, J. Chem. Theory Comput., 11, 3696, 10.1021/acs.jctc.5b00255 Träg, 2019, Improved GAFF2 parameters for fluorinated alkanes and mixed hydro and fluorocarbons, J. Mol. Model., 25, 39, 10.1007/s00894-018-3911-5 Wang, 2006, Automatic atom type and bond type perception in molecular mechanical calculations, J. Mol. Graph. Model., 25, 247, 10.1016/j.jmgm.2005.12.005 Jorgensen, 1983, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys., 79, 926, 10.1063/1.445869 Joung, 2008, Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations, J. Phys. Chem. B, 112, 9020, 10.1021/jp8001614 Loncharich, 1992, Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide, Biopolymers, 32, 523, 10.1002/bip.360320508 Lin, 2017, Application of Berendsen barostat in dissipative particle dynamics for nonequilibrium dynamic simulation, J. Chem. Phys., 146, 10.1063/1.4978807 Roe, 2013, PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data, J. Chem. Theory Comput., 9, 3084, 10.1021/ct400341p Humphrey, 1996, VMD: Visual molecular dynamics, J. Mol. Graph., 14, 33, 10.1016/0263-7855(96)00018-5 Daina, 2017, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep., 7, 42717, 10.1038/srep42717 Daina, 2014, iLOGP: A simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach, J. Chem. Inf. Model., 54, 3284, 10.1021/ci500467k Daina, 2016, A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules, ChemMedChem, 11, 1117, 10.1002/cmdc.201600182 Khan, 2021, Utilization of the common functional groups in bioactive molecules: Exploring dual inhibitory potential and computational analysis of keto esters against α-glucosidase and carbonic anhydrase-II enzymes, Int. J. Biol. Macromol., 167, 233, 10.1016/j.ijbiomac.2020.11.170 Ertl, 2000, Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties, J. Med. Chem., 43, 3714, 10.1021/jm000942e